Equities analysts expect Insys Therapeutics Inc (NASDAQ:INSY) to post earnings of ($0.15) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Insys Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.12). Insys Therapeutics reported earnings of $0.03 per share during the same quarter last year, which suggests a negative year over year growth rate of 600%. The business is scheduled to report its next earnings results on Thursday, August 2nd.

On average, analysts expect that Insys Therapeutics will report full year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.64) to ($0.58). For the next fiscal year, analysts forecast that the company will report earnings of ($0.27) per share, with EPS estimates ranging from ($0.33) to ($0.20). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Insys Therapeutics.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.01). Insys Therapeutics had a negative return on equity of 43.27% and a negative net margin of 188.01%. The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $25.82 million. During the same period in the previous year, the business earned ($0.09) earnings per share. Insys Therapeutics’s revenue was down 33.4% on a year-over-year basis.

A number of equities analysts have recently commented on INSY shares. ValuEngine raised Insys Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 15th. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 28th. Finally, Oppenheimer reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Wednesday, May 9th. Three analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $9.38.

In related news, Director Brian Tambi sold 166,504 shares of the stock in a transaction on Thursday, May 10th. The stock was sold at an average price of $6.41, for a total value of $1,067,290.64. Following the sale, the director now owns 4,000 shares in the company, valued at $25,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 67.90% of the company’s stock.

Several hedge funds have recently modified their holdings of INSY. Stone Ridge Asset Management LLC purchased a new stake in shares of Insys Therapeutics in the fourth quarter worth $137,000. JPMorgan Chase & Co. raised its position in shares of Insys Therapeutics by 303.5% in the first quarter. JPMorgan Chase & Co. now owns 25,624 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 19,273 shares in the last quarter. Virtu Financial LLC raised its position in shares of Insys Therapeutics by 96.8% in the fourth quarter. Virtu Financial LLC now owns 20,061 shares of the specialty pharmaceutical company’s stock worth $193,000 after buying an additional 9,866 shares in the last quarter. Raymond James & Associates raised its position in Insys Therapeutics by 93.5% during the fourth quarter. Raymond James & Associates now owns 31,008 shares of the specialty pharmaceutical company’s stock valued at $298,000 after purchasing an additional 14,982 shares in the last quarter. Finally, Deutsche Bank AG raised its position in Insys Therapeutics by 116.1% during the fourth quarter. Deutsche Bank AG now owns 53,827 shares of the specialty pharmaceutical company’s stock valued at $515,000 after purchasing an additional 28,923 shares in the last quarter. Institutional investors own 17.78% of the company’s stock.

Insys Therapeutics stock opened at $7.65 on Monday. Insys Therapeutics has a one year low of $4.10 and a one year high of $14.00. The firm has a market capitalization of $561.69 million, a PE ratio of -15.61 and a beta of 1.21.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.